![Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore](https://www.sanita24.ilsole24ore.com/images2014/Editrice/ILSOLE24ORE/QUOTIDIANO_SANITA/2022/09/15/Quotidiano%20Sanita/ImmaginiWeb/Clipboard-0016.png)
Covid: Aifa approva il vaccino bivalente Comirnaty sviluppato contro Omicron 4-5 | Sanità24 - Il Sole 24 Ore
Moderna su LinkedIn: Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214… | 13 commenti
![Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology](https://www.science.org/cms/10.1126/sciimmunol.ade9888/asset/48a118e9-748c-4457-aef2-878a8451c21c/assets/images/large/sciimmunol.ade9888-f3.jpg)
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice | Science Immunology
![Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-075286/F1.large.jpg)
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
![Omicron boosters: Do I need another COVID-19 shot, and when? | COVID | Prevention | UT Southwestern Medical Center Omicron boosters: Do I need another COVID-19 shot, and when? | COVID | Prevention | UT Southwestern Medical Center](https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/original_images/Omicron_booster_copy.jpg)
Omicron boosters: Do I need another COVID-19 shot, and when? | COVID | Prevention | UT Southwestern Medical Center
![Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of](https://pbs.twimg.com/media/FZ43mJXVEAAJxnK.jpg)
Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of
![AIFA autorizza il vaccino bivalente Comirnaty Original per le varianti Omicron BA.4-5 – Centro Regionale FarmacoVigilanza Sardegna AIFA autorizza il vaccino bivalente Comirnaty Original per le varianti Omicron BA.4-5 – Centro Regionale FarmacoVigilanza Sardegna](https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png)
AIFA autorizza il vaccino bivalente Comirnaty Original per le varianti Omicron BA.4-5 – Centro Regionale FarmacoVigilanza Sardegna
![Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_736452_1674469663421306.jpg)
Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death
![News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut](https://www.pei.de/SharedDocs/Bilder/EN/newsroom-en/hp-news-pm/omicron-ba5-chmp.jpg?__blob=thumbnail&v=6)
News - CHMP Recommends Additional Authorisation Modification of Comirnaty (BioNTech/Pfizer) As a Bivalent Vaccine Adapted to Omicron BA.4/BA.5 for Booster Vaccinations - Paul-Ehrlich-Institut
![Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health](https://publichealth.jhu.edu/sites/default/files/styles/social_image/public/2023-02/bivalent-vaccine-g1422104879.jpg?itok=mgeH3XVw)
Common Questions About Bivalent COVID-19 Boosters | Johns Hopkins | Bloomberg School of Public Health
BioNTech SE on LinkedIn: Pfizer and BioNTech Report New Data on Omicron BA.4 /BA.5-Adapted Bivalent…
CDC on X: "The updated #COVID19 booster can both help restore protection that has waned since the previous vaccination and provide broader protection against newer BA.4 and BA.5 Omicron subvariants. Learn more:
![Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN](https://dynaimage.cdn.cnn.com/cnn/c_fill,g_auto,w_1200,h_675,ar_16:9/https%3A%2F%2Fcdn.cnn.com%2Fcnnnext%2Fdam%2Fassets%2F221024193034-covid-19-booster-090922.jpg)
Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN
![Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ](https://www.bmj.com/content/bmj/382/bmj-2022-075286/F3.medium.jpg)